Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Raw Materials (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Raw Materials over the past 3 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Raw Materials at $2.5 million for Q4 2025, down 18.4% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (down 18.4% YoY), and the annual figure for FY2025 was $2.5 million, down 18.4%.
  • Raw Materials for Q4 2025 was $2.5 million at Tonix Pharmaceuticals Holding, up from $2.5 million in the prior quarter.
  • Over the last five years, Raw Materials for TNXP hit a ceiling of $3.6 million in Q4 2023 and a floor of $2.3 million in Q2 2025.
  • Median Raw Materials over the past 3 years was $2.7 million (2025), compared with a mean of $2.9 million.
  • Biggest five-year swings in Raw Materials: dropped 14.95% in 2024 and later fell 25.82% in 2025.
  • Tonix Pharmaceuticals Holding's Raw Materials stood at $3.6 million in 2023, then decreased by 14.95% to $3.1 million in 2024, then dropped by 18.4% to $2.5 million in 2025.
  • The last three reported values for Raw Materials were $2.5 million (Q4 2025), $2.5 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.